Original ArticleHarms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events
Keywords
Cited by (0)
Data sharing: Statistical code and datasets are available from the Dryad repository, https://doi.org/10.5061/dryad.mp26fb1.
Funding: This study was supported by contract ME 1303 5785 from the Patient Centered Outcomes Research Institute (PCORI) and funds established for scholarly research on reporting biases at Johns Hopkins University by Greene LLP. The funders were not involved in the design or conduct of the study, article preparation, or the decision to submit the article for publication.
Ethics approval: The study received an exemption from the Johns Hopkins Bloomberg School of Public Health Institutional Review Board (IRB No: 00006324).
Conflict of interest: Up to 2008, K.D. served as an unpaid expert witness for the plaintiffs' lawyers in litigation against Pfizer that provided several gabapentin documents used for this study. Swaroop Vedula was paid by the plaintiffs' attorneys for research assistance provided to K.D. for her work as an expert witness. Greene LLP, a law firm that has represented various clients in litigation against Pfizer, including the case in which K.D. served as an expert witness, provided a fund for scholarly research on reporting biases that partially covered salaries of some investigators performing analysis and interpretation of data.
For the collaborators: Terrie Cowley is President of The TMJ Association, Ltd., which received funding from Pfizer from 2009 to 2011 (for the Campaign to End Chronic Pain in Women) and from Purdue Pharma, L.P. in 2008, 2010, and 2012 to 2016 (to support the TMJ Association science meeting and develop educational materials based on scientific research advances). Peter Doshi was a corecipient of a UK National Institute for Health Research grant (HTA – 10/80/01 Update and amalgamation of two Cochrane reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children—http://www.nets.nihr.ac.uk/projects/hta/108001). Peter Doshi received €1,500 from the European Respiratory Society in support of his travel to the society's September 2012 annual congress in Vienna, where he gave an invited talk on oseltamivir. Peter Doshi gratefully acknowledges the American Association of Colleges of Pharmacy for its funding support ($11,000) for a study to analyze written medical information regarding the possible harms of statins. AACP had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of this article. Peter Doshi is also an associate editor of The BMJ and an unpaid member of the IMEDS steering committee at the Reagan-Udall Foundation for the FDA, which focuses on drug safety research.
- 1
These authors contributed equally to this article.